📊 TBPH Key Takeaways
Is Theravance Biopharma, Inc. (TBPH) a Good Investment?
Early-stage biotech with strong 66.9% revenue growth, fortress balance sheet ($288M cash, zero debt), and positive operating cash flow indicating quality revenue generation. While still unprofitable, improving fundamentals (EPS up 279% YoY) and exceptional liquidity provide multi-year runway to commercialization, creating favorable risk/reward for patient capital.
Theravance Biopharma, Inc. Key Strengths (TBPH)
- Strong revenue growth of 66.9% YoY demonstrating successful product commercialization
- Fortress balance sheet with $288M cash equivalents, zero long-term debt, and 13.14x current ratio
- Positive operating cash flow of $73.3M despite net losses indicates high-quality revenue and efficient cash management
TBPH Stock Risks: Theravance Biopharma, Inc. Investment Risks
- Company remains deeply unprofitable with -27.9% net margin and -53.6% operating margin
- Path to operating profitability unproven as operating expenses currently exceed revenue
- Early-stage commercial portfolio subject to regulatory/clinical execution risk and product adoption uncertainty
Key Metrics to Watch
- Revenue growth rate sustainability and product market penetration trends
- Operating expense ratio and timeline to operating profitability at current revenue trajectory
- Quarterly cash burn rate and cash runway sufficiency relative to pipeline development
Theravance Biopharma, Inc. (TBPH) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 413.8% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 13.14x current ratio provides a solid financial cushion.
TBPH Profit Margin, ROE & Profitability Analysis
TBPH vs Healthcare Sector: How Theravance Biopharma, Inc. Compares
How Theravance Biopharma, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Theravance Biopharma, Inc. Stock Overvalued? TBPH Valuation Analysis 2026
Based on fundamental analysis, Theravance Biopharma, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Theravance Biopharma, Inc. Balance Sheet: TBPH Debt, Cash & Liquidity
TBPH Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Theravance Biopharma, Inc.'s revenue has grown significantly by 46% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.24 indicates the company is currently unprofitable.
TBPH Revenue Growth, EPS Growth & YoY Performance
TBPH Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $15.4M | -$4.9M | $-0.10 |
| Q3 2025 | $16.9M | $3.6M | $0.07 |
| Q2 2025 | $14.3M | -$16.5M | $-0.34 |
| Q1 2025 | $14.5M | -$11.7M | $-0.24 |
| Q3 2024 | $15.7M | -$9.0M | $-0.17 |
| Q2 2024 | $13.7M | -$15.6M | $-0.28 |
| Q1 2024 | $10.4M | -$11.7M | $-0.24 |
| Q3 2023 | $12.5M | -$9.0M | $-0.17 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Theravance Biopharma, Inc. Dividends, Buybacks & Capital Allocation
TBPH SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Theravance Biopharma, Inc. (CIK: 0001583107)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| May 22, 2026 | 4 | xslF345X06/form4-05222026_100553.xml | View → |
| May 22, 2026 | 4 | xslF345X06/form4-05222026_100506.xml | View → |
| May 22, 2026 | 4 | xslF345X06/form4-05222026_100507.xml | View → |
| May 22, 2026 | 4 | xslF345X06/form4-05222026_100551.xml | View → |
| May 22, 2026 | 4 | xslF345X06/form4-05222026_100557.xml | View → |
❓ Frequently Asked Questions about TBPH
What is the AI rating for TBPH?
Theravance Biopharma, Inc. (TBPH) has an AI grade of A with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TBPH's key strengths?
Claude: Strong revenue growth of 66.9% YoY demonstrating successful product commercialization. Fortress balance sheet with $288M cash equivalents, zero long-term debt, and 13.14x current ratio.
What are the risks of investing in TBPH?
Claude: Company remains deeply unprofitable with -27.9% net margin and -53.6% operating margin. Path to operating profitability unproven as operating expenses currently exceed revenue.
What is TBPH's revenue and growth?
Theravance Biopharma, Inc. reported revenue of $17.7M.
Does TBPH pay dividends?
Theravance Biopharma, Inc. does not currently pay dividends.
Where can I find TBPH SEC filings?
Official SEC filings for Theravance Biopharma, Inc. (CIK: 0001583107) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TBPH's EPS?
Theravance Biopharma, Inc. has a diluted EPS of $-0.10.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is TBPH's fundamental grade?
Based on our AI fundamental analysis in June 2026, Theravance Biopharma, Inc. has a A grade with 72% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is TBPH stock overvalued or undervalued?
Valuation metrics for TBPH: ROE of -1.7% (sector avg: 15%), net margin of -27.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is TBPH's AI grade for 2026?
Our dual AI analysis gives Theravance Biopharma, Inc. a combined A grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TBPH's free cash flow?
Theravance Biopharma, Inc.'s operating cash flow is $73.3M, with capital expenditures of $42.0K. FCF margin is 413.8%.
How does TBPH compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -27.9% (avg: 12%), ROE -1.7% (avg: 15%), current ratio 13.14 (avg: 2).